Tandem Diabetes Care (TNDM) Capital Expenditures Growth (1y) (2014 - 2026)
Tandem Diabetes Care (TNDM) Capital Expenditures Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.52 Bn | 176.22 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 128.83 Bn | 125.95 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 108.61 Bn | 99.39 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 68.35 Bn | 66.90 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 48.53 Bn | 44.86 Bn | 1.29 Bn | 15.89% |
| 6 | Dexcom | 28.42 Bn | 27.30 Bn | 750.30 Mn | -11.95% |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn | 106.98% |
| 8 | Smith & Nephew | 26.92 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 25.49 Bn | 22.36 Bn | 2.07 Bn | -47.73% |
| 10 | Tandem Diabetes Care | 1.14 Bn | 574.03 Mn | 136.79 Mn | 111.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 111.40% |
| Dec 31, 2025 | 139.20% |
| Sep 30, 2025 | 132.68% |
| Jun 30, 2025 | -124.54% |
| Mar 31, 2025 | -7.75% |
| Dec 31, 2024 | -1,085.84% |
| Sep 30, 2024 | 134.95% |
| Jun 30, 2024 | 4.50% |
| Mar 31, 2024 | -63.59% |
| Dec 31, 2023 | 600.40% |
| Sep 30, 2023 | -4,981.02% |
| Jun 30, 2023 | 996.14% |
| Mar 31, 2023 | 1,416.84% |
| Dec 31, 2022 | -71.93% |
| Sep 30, 2022 | -5,800.00% |
| Jun 30, 2022 | 373.94% |
| Mar 31, 2022 | 3,323.53% |
| Dec 31, 2021 | -78.52% |
| Sep 30, 2021 | -100.02% |
| Jun 30, 2021 | 102.45% |